

**Exhibit 1009**

**DECLARATION OF MATTHEW W. DAVIS M.D. RPH.**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re *Inter Partes Review* : PETITION FOR *INTER PARTES* REVIEW OF  
U.S. PATENT NO. 6,315,720 UNDER 35 USC §§  
311-319 AND 37 CFR §42.100 ET SEQ.

Case No. : To be Assigned

Petitioner : To be Named

Filed :

Attorney Docket No. :

Customer No. : 27571

Appeal Related Matters

Patent Trial and Appeal Board

US Patent and Trademark Office

PO Box 1450

Alexandria, Virginia 22313-1450

**DECLARATION OF MATTHEW W. DAVIS M.D. R.Ph.**

Sir:

I, the undersigned, hereby declare the following, based on my own  
knowledge, information, and belief:

1. I am presently Senior Vice President of Clinical Operations and Development at Sun Pharmaceuticals.
  
2. I received an M.D. degree from the Medical College of Pennsylvania in 1994 and a B.S. in Pharmacy from Temple University School of Pharmacy. I did an internship in surgery, followed by a residency in urology. I am a registered pharmacist, R.Ph, as well as a licensed physician.
  
3. Since 1998, I have directed clinical development and medical affairs at a number of different companies. These companies include, Endo Pharmaceuticals, Dermik Laboratories, Dr. Reddy's Laboratories, Eisai Global Research and most recently, URL Pharma, now Sun Pharmaceuticals.
  
4. I have co-authored 20 articles in peer reviewed scientific and medical journals. I am the sole inventor of 17 U.S. patents, named inventor on numerous other patents and patent applications. A copy of my resume is attached.
  
5. I have reviewed U.S. Patent No. 6,315,720, its file history as well as the prior art cited in the Petition: (i) Powell et al. (Postgrad. Med. J. 70:901 (1994)),

(“Powell”), *Exhibit 1002*); (ii) Dishman et al. (Am. J. Hosp. Pharm 51: 899 (1994), (“Dishman”), *Exhibit 1003*); (iii) Bastani et al. (Psychopharmacology 99:S122 (1989), (Bastani”), *Exhibit 1004*); (iv) Mitchell et al. (New England J. Med. 333(2):101 (1995), (“Mitchell”), *Exhibit 1007*); (v) Honigfeld (Psychiatric Services 47:52 (1996), (“Honigfeld”), *Exhibit 1008*); (vi) the 47th Meeting of the Dermatologic and Ophthalmic Advisory Board (September 4-5, 1997, (the “FDA Meeting”), *Exhibit 1005 (a) and (b)*); and (ix) CDC Meeting (Centers for Disease Control, Preventing Birth Defects, March 26, 1997, (the “CDC Meeting”), *Exhibit 1006*).

6. The medical community was acutely aware of the need to put in-place a program for tightly controlling the distribution of drugs causing adverse side effects. In fact, there were numerous drug dispensing and restriction programs in place in the mid to late 1990’s, including: (i) restricted distribution (Fentanyl, Oralet); (ii) limited quantity (Clozaril); (iii) consent (Accutane, Felbatol); (iv) laboratory testing (Clozaril/ requiring a white blood count); (v) registry (AZT, Acyclovir); and, (vi) patient/provider education (Accutane). *Exhibit 1006 at 8*. I found the following statements from FDA and CDC meetings held in 1997 especially informative.

7. Dr. Bergfeld recommended the system (STEPS) “What I would like to recommend is that registry for the physician include that they have signed off on an informed consent that they have been informed about the information, they have read it, and they agree to participate in that manner.” Dr. Williams then responded, “[t]hat is reasonable.” (*Exhibit 1005(a) at 121*).

8. Dr. Woodcock from the FDA stated “the need to impose a mandatory restriction, under regulation, depends on our judgment of whether that is necessary to ensure the safety of the product. So, it really depends on how safe we feel the safety would be under a voluntary system or whatever safety is available compared to the need for additional safety that would merit, that would require for approval a restricted distribution.” (*Exhibit 1005(a) at 220*).

9. Finally, Dr. Williams stated that, “[t]he other thing is that the way the system is being developed, it would be designed to utilize some of the systems that are currently in place within pharmacy practice where there are central computer databases that pharmacists log in and out on when they are filling prescriptions. A portion of one of those databases will be carved out to actually have the pharmacist tracking and recording information on this patient so that we’d be in a position to

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.